 Maura Gasparetto
Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aldehyde Dehydrogenase | 8 | 2017 | 130 | 2.310 |
Why?
| | Leukemia, Myeloid, Acute | 9 | 2023 | 531 | 1.700 |
Why?
| | Hematopoietic Stem Cells | 8 | 2017 | 356 | 1.500 |
Why?
| | Cytarabine | 1 | 2019 | 52 | 0.660 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2019 | 82 | 0.640 |
Why?
| | Cation Transport Proteins | 1 | 2019 | 98 | 0.630 |
Why?
| | Flow Cytometry | 8 | 2012 | 1045 | 0.530 |
Why?
| | Hematologic Neoplasms | 1 | 2017 | 133 | 0.520 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1045 | 0.520 |
Why?
| | Cell Proliferation | 4 | 2019 | 2197 | 0.510 |
Why?
| | Hematopoiesis | 3 | 2015 | 175 | 0.510 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 958 | 0.470 |
Why?
| | Antigens, Differentiation | 2 | 2012 | 79 | 0.430 |
Why?
| | G1 Phase | 2 | 2012 | 68 | 0.430 |
Why?
| | Adult Stem Cells | 1 | 2012 | 32 | 0.410 |
Why?
| | Hematopoietic Stem Cell Transplantation | 6 | 2012 | 519 | 0.360 |
Why?
| | Graft Survival | 1 | 2012 | 481 | 0.350 |
Why?
| | Neoplastic Stem Cells | 4 | 2023 | 330 | 0.320 |
Why?
| | Cell Self Renewal | 2 | 2019 | 50 | 0.310 |
Why?
| | B-Lymphocytes | 1 | 2011 | 770 | 0.280 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2016 | 92 | 0.260 |
Why?
| | Antineoplastic Agents | 6 | 2017 | 1890 | 0.250 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2017 | 304 | 0.250 |
Why?
| | Retinal Dehydrogenase | 2 | 2017 | 38 | 0.250 |
Why?
| | Fetal Blood | 2 | 2017 | 268 | 0.240 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2004 | 180 | 0.230 |
Why?
| | Mice | 12 | 2019 | 15075 | 0.230 |
Why?
| | Lymphoma | 1 | 2004 | 176 | 0.220 |
Why?
| | Reactive Oxygen Species | 2 | 2017 | 548 | 0.210 |
Why?
| | Cell Separation | 5 | 2011 | 290 | 0.200 |
Why?
| | Prognosis | 3 | 2019 | 3337 | 0.200 |
Why?
| | Cells, Cultured | 5 | 2019 | 3879 | 0.190 |
Why?
| | Animals | 16 | 2019 | 32091 | 0.190 |
Why?
| | Antibodies, Monoclonal | 3 | 2007 | 1259 | 0.170 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 178 | 0.170 |
Why?
| | Nuclear Pore Complex Proteins | 2 | 2011 | 32 | 0.170 |
Why?
| | Leukopoiesis | 1 | 2019 | 10 | 0.170 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 16 | 0.170 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 29 | 0.170 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 42 | 0.170 |
Why?
| | DNA Damage | 2 | 2011 | 348 | 0.170 |
Why?
| | Tumor Cells, Cultured | 2 | 2019 | 840 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2017 | 646 | 0.160 |
Why?
| | Bone Marrow Cells | 2 | 2017 | 272 | 0.160 |
Why?
| | Fusion Proteins, bcr-abl | 3 | 2012 | 60 | 0.150 |
Why?
| | Blood Cells | 1 | 2017 | 39 | 0.150 |
Why?
| | Mice, Inbred C57BL | 8 | 2019 | 4770 | 0.150 |
Why?
| | Arsenicals | 1 | 2017 | 24 | 0.140 |
Why?
| | Oxides | 1 | 2017 | 41 | 0.140 |
Why?
| | Leukemia | 1 | 2019 | 207 | 0.140 |
Why?
| | Recombinant Fusion Proteins | 2 | 2011 | 620 | 0.140 |
Why?
| | Cyclophosphamide | 1 | 2017 | 217 | 0.140 |
Why?
| | Heterografts | 1 | 2017 | 121 | 0.140 |
Why?
| | Isoenzymes | 1 | 2017 | 286 | 0.140 |
Why?
| | Enzyme Inhibitors | 2 | 2013 | 749 | 0.130 |
Why?
| | Homeodomain Proteins | 2 | 2011 | 465 | 0.130 |
Why?
| | Cell Cycle | 2 | 2011 | 541 | 0.130 |
Why?
| | Animals, Congenic | 2 | 2011 | 10 | 0.120 |
Why?
| | Radiation Chimera | 2 | 2011 | 31 | 0.120 |
Why?
| | Survival Rate | 1 | 2019 | 1663 | 0.120 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 351 | 0.120 |
Why?
| | Gene Deletion | 2 | 2012 | 355 | 0.120 |
Why?
| | Benzaldehydes | 1 | 2013 | 8 | 0.120 |
Why?
| | Disulfiram | 1 | 2013 | 12 | 0.120 |
Why?
| | Neoplasms, Experimental | 1 | 2014 | 153 | 0.120 |
Why?
| | Humans | 18 | 2023 | 115297 | 0.110 |
Why?
| | Myelodysplastic Syndromes | 1 | 2015 | 118 | 0.110 |
Why?
| | Piperazines | 2 | 2007 | 314 | 0.110 |
Why?
| | Adenosine Deaminase | 1 | 2012 | 26 | 0.110 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2014 | 177 | 0.110 |
Why?
| | Adaptation, Physiological | 1 | 2016 | 476 | 0.110 |
Why?
| | Adipose Tissue | 1 | 2016 | 558 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2014 | 282 | 0.100 |
Why?
| | Pyrimidines | 2 | 2007 | 377 | 0.100 |
Why?
| | Colony-Forming Units Assay | 1 | 2011 | 92 | 0.100 |
Why?
| | Enzyme Induction | 1 | 2011 | 89 | 0.100 |
Why?
| | Lymphopenia | 1 | 2011 | 49 | 0.100 |
Why?
| | Mice, Knockout | 3 | 2016 | 2607 | 0.100 |
Why?
| | Transcription Factors | 2 | 2011 | 1531 | 0.100 |
Why?
| | Cell Culture Techniques | 2 | 2011 | 346 | 0.100 |
Why?
| | Cell Count | 1 | 2011 | 304 | 0.100 |
Why?
| | Transplantation, Homologous | 1 | 2012 | 395 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 252 | 0.090 |
Why?
| | Aldehydes | 1 | 2011 | 145 | 0.090 |
Why?
| | Mice, Transgenic | 2 | 2014 | 1973 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2017 | 620 | 0.090 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 241 | 0.090 |
Why?
| | Blast Crisis | 2 | 2016 | 19 | 0.090 |
Why?
| | Ethanol | 1 | 2015 | 563 | 0.090 |
Why?
| | Cell Lineage | 1 | 2011 | 311 | 0.090 |
Why?
| | E2F4 Transcription Factor | 1 | 2009 | 6 | 0.090 |
Why?
| | E2F3 Transcription Factor | 1 | 2009 | 8 | 0.090 |
Why?
| | E2F2 Transcription Factor | 1 | 2009 | 15 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2017 | 3565 | 0.090 |
Why?
| | E2F1 Transcription Factor | 1 | 2009 | 57 | 0.090 |
Why?
| | Programming Languages | 1 | 2009 | 23 | 0.090 |
Why?
| | Telomerase | 1 | 2011 | 203 | 0.080 |
Why?
| | Telomere | 1 | 2011 | 204 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2009 | 114 | 0.080 |
Why?
| | Lymphoma, B-Cell | 1 | 2009 | 83 | 0.080 |
Why?
| | Information Storage and Retrieval | 1 | 2009 | 109 | 0.080 |
Why?
| | Database Management Systems | 1 | 2008 | 48 | 0.080 |
Why?
| | Graft vs Host Disease | 2 | 2007 | 209 | 0.080 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2007 | 80 | 0.080 |
Why?
| | Lymphocytes | 2 | 2007 | 337 | 0.080 |
Why?
| | Rituximab | 2 | 2007 | 149 | 0.070 |
Why?
| | Antigens, CD34 | 2 | 2023 | 97 | 0.070 |
Why?
| | Computer Graphics | 1 | 2007 | 44 | 0.070 |
Why?
| | Guidelines as Topic | 1 | 2008 | 243 | 0.070 |
Why?
| | Artifacts | 1 | 2007 | 124 | 0.070 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2007 | 69 | 0.070 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2366 | 0.070 |
Why?
| | Computational Biology | 1 | 2009 | 525 | 0.060 |
Why?
| | Aphidicolin | 1 | 2004 | 5 | 0.060 |
Why?
| | Phenanthrolines | 1 | 2004 | 8 | 0.060 |
Why?
| | Topotecan | 1 | 2004 | 13 | 0.060 |
Why?
| | Apoptosis | 2 | 2004 | 2363 | 0.060 |
Why?
| | Multienzyme Complexes | 1 | 2003 | 64 | 0.060 |
Why?
| | Cysteine Endopeptidases | 1 | 2003 | 61 | 0.060 |
Why?
| | Hydroxamic Acids | 1 | 2003 | 80 | 0.060 |
Why?
| | Software | 1 | 2007 | 533 | 0.050 |
Why?
| | Leukapheresis | 1 | 2002 | 21 | 0.050 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2002 | 19 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 1805 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2003 | 199 | 0.050 |
Why?
| | Muscle Proteins | 1 | 2003 | 215 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 139 | 0.050 |
Why?
| | Immunophenotyping | 3 | 2009 | 272 | 0.050 |
Why?
| | Cell Line, Tumor | 2 | 2007 | 2756 | 0.050 |
Why?
| | Azacitidine | 1 | 2022 | 127 | 0.050 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 171 | 0.050 |
Why?
| | Sulfonamides | 1 | 2022 | 446 | 0.040 |
Why?
| | Machine Learning | 1 | 2022 | 318 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2002 | 437 | 0.040 |
Why?
| | Signal Transduction | 1 | 2011 | 4537 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 174 | 0.040 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2017 | 32 | 0.040 |
Why?
| | Stem Cells | 1 | 2002 | 542 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2019 | 610 | 0.040 |
Why?
| | Gonads | 1 | 2016 | 21 | 0.030 |
Why?
| | CD36 Antigens | 1 | 2016 | 39 | 0.030 |
Why?
| | Cytoprotection | 1 | 2016 | 52 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2423 | 0.030 |
Why?
| | Lipolysis | 1 | 2016 | 38 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2002 | 1032 | 0.030 |
Why?
| | Antigens, CD | 2 | 2009 | 442 | 0.030 |
Why?
| | Imatinib Mesylate | 2 | 2007 | 64 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 267 | 0.030 |
Why?
| | Benzamides | 2 | 2007 | 170 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1359 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2014 | 56 | 0.030 |
Why?
| | Mice, SCID | 1 | 2014 | 321 | 0.030 |
Why?
| | Half-Life | 1 | 2013 | 146 | 0.030 |
Why?
| | Fatty Acids | 1 | 2016 | 393 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 887 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1634 | 0.030 |
Why?
| | Adenosine Deaminase Inhibitors | 1 | 2012 | 2 | 0.030 |
Why?
| | Area Under Curve | 1 | 2013 | 277 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2014 | 559 | 0.030 |
Why?
| | Drug Interactions | 1 | 2013 | 343 | 0.030 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2013 | 134 | 0.030 |
Why?
| | Trans-Activators | 1 | 2014 | 366 | 0.030 |
Why?
| | Tamoxifen | 1 | 2012 | 195 | 0.020 |
Why?
| | DNA Primers | 1 | 2012 | 514 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2016 | 714 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2011 | 114 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2002 | 1858 | 0.020 |
Why?
| | Protein Engineering | 1 | 2011 | 105 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 942 | 0.020 |
Why?
| | Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2009 | 1 | 0.020 |
Why?
| | rhoB GTP-Binding Protein | 1 | 2009 | 2 | 0.020 |
Why?
| | Phospholipase D | 1 | 2009 | 7 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2009 | 74 | 0.020 |
Why?
| | von Willebrand Factor | 1 | 2009 | 55 | 0.020 |
Why?
| | Base Sequence | 1 | 2012 | 2104 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2022 | 9127 | 0.020 |
Why?
| | Indicators and Reagents | 1 | 2008 | 99 | 0.020 |
Why?
| | Miniaturization | 1 | 2007 | 24 | 0.020 |
Why?
| | Specimen Handling | 1 | 2008 | 154 | 0.020 |
Why?
| | Octamer Transcription Factor-1 | 1 | 2007 | 3 | 0.020 |
Why?
| | Interleukin-3 | 1 | 2007 | 23 | 0.020 |
Why?
| | Cell Division | 1 | 2009 | 752 | 0.020 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2007 | 36 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2007 | 69 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 355 | 0.020 |
Why?
| | Time | 1 | 2007 | 73 | 0.020 |
Why?
| | CD3 Complex | 1 | 2007 | 92 | 0.020 |
Why?
| | Quality Control | 1 | 2007 | 151 | 0.020 |
Why?
| | CD4 Antigens | 1 | 2007 | 124 | 0.020 |
Why?
| | Histones | 1 | 2011 | 535 | 0.020 |
Why?
| | Female | 4 | 2019 | 59773 | 0.020 |
Why?
| | Inflammation | 1 | 2016 | 2482 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2007 | 469 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 326 | 0.020 |
Why?
| | Databases, Factual | 1 | 2009 | 1157 | 0.010 |
Why?
| | Time Factors | 2 | 2007 | 6133 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 374 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1142 | 0.010 |
Why?
| | Cell Survival | 1 | 2007 | 1011 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 78 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2007 | 1051 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 107 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2003 | 137 | 0.010 |
Why?
| | Acetylation | 1 | 2003 | 212 | 0.010 |
Why?
| | Phosphorylation | 1 | 2007 | 1569 | 0.010 |
Why?
| | Microfilament Proteins | 1 | 2003 | 127 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2007 | 591 | 0.010 |
Why?
| | Pyridones | 1 | 2003 | 122 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2009 | 1567 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1716 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2002 | 401 | 0.010 |
Why?
| | Algorithms | 1 | 2007 | 1488 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2007 | 2811 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2003 | 1127 | 0.010 |
Why?
| | Biomarkers | 1 | 2007 | 3450 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2002 | 1710 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2002 | 1751 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 2854 | 0.010 |
Why?
| | Male | 1 | 2009 | 55796 | 0.000 |
Why?
|
|
Gasparetto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|